Logo image of SIOX

SIO GENE THERAPIES INC (SIOX) Stock Fundamental Analysis

NASDAQ:SIOX - US8293991043 - Common Stock

0.415 USD
+0.01 (+2.09%)
Last: 3/22/2023, 8:00:04 PM
0.4151 USD
+0 (+0.02%)
After Hours: 3/22/2023, 8:00:04 PM
Fundamental Rating

2

Taking everything into account, SIOX scores 2 out of 10 in our fundamental rating. SIOX was compared to 549 industry peers in the Biotechnology industry. The financial health of SIOX is average, but there are quite some concerns on its profitability. SIOX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SIOX had negative earnings in the past year.
SIOX had a negative operating cash flow in the past year.
In the past 5 years SIOX always reported negative net income.
In the past 5 years SIOX always reported negative operating cash flow.
SIOX Yearly Net Income VS EBIT VS OCF VS FCFSIOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M -200M

1.2 Ratios

SIOX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SIOX Yearly ROA, ROE, ROICSIOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

SIOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SIOX Yearly Profit, Operating, Gross MarginsSIOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SIOX has been increased compared to 1 year ago.
SIOX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SIOX Yearly Shares OutstandingSIOX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
SIOX Yearly Total Debt VS Total AssetsSIOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -20.96, we must say that SIOX is in the distress zone and has some risk of bankruptcy.
SIOX has a Altman-Z score of -20.96. This is amonst the worse of the industry: SIOX underperforms 87.48% of its industry peers.
SIOX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.96
ROIC/WACCN/A
WACCN/A
SIOX Yearly LT Debt VS Equity VS FCFSIOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

SIOX has a Current Ratio of 11.12. This indicates that SIOX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SIOX (11.12) is better than 77.50% of its industry peers.
A Quick Ratio of 11.12 indicates that SIOX has no problem at all paying its short term obligations.
SIOX has a better Quick ratio (11.12) than 77.50% of its industry peers.
Industry RankSector Rank
Current Ratio 11.12
Quick Ratio 11.12
SIOX Yearly Current Assets VS Current LiabilitesSIOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.86% over the past year.
EPS 1Y (TTM)2.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SIOX Yearly EPS VS EstimatesSIOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SIOX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SIOX Price Earnings VS Forward Price EarningsSIOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SIOX Per share dataSIOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SIOX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIO GENE THERAPIES INC

NASDAQ:SIOX (3/22/2023, 8:00:04 PM)

After market: 0.4151 +0 (+0.02%)

0.415

+0.01 (+2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2023-02-10/bmo
Earnings (Next)06-12 2023-06-12/bmo
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.42%
Ins Owner Change0%
Market Cap30.70M
Analysts85.71
Price Target5.1 (1128.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 279.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.12
Quick Ratio 11.12
Altman-Z -20.96
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.34%
Cap/Depr(5y)93.23%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.21%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.31%
OCF growth 3YN/A
OCF growth 5YN/A